DETERMINATION OF CYP2D6 PHENOTYPING FOR METOPROLOL USING THE CYP2D6 GENOTYPE-DERIVED ACTIVITY SCORE: RESULTS FROM A PROSPECTIVE, CLINICAL TRIAL.

被引：0
|
作者：
Thomas, C. D. [1 ]
Mosley, S. A. [1 ]
El Rouby, N. [1 ]
Kim, S. [2 ]
Lingineni, K. [2 ]
Langaee, T. [1 ]
Gong, Y. [1 ]
Johnson, J. A. [1 ]
Schmidt, S. O. [1 ]
Schmidt, S. [2 ]
Frye, R. F. [1 ]
Cavallari, L. H. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Univ Florida, Orlando, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
LB-028
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [21] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [22] CYP2D6 genotype and tamoxifen response
    Rae, JM
    Goetz, MP
    Hayes, DF
    Ingle, JN
    Li, L
    Storniolo, AM
    Stearns, V
    Flockhart, DA
    BREAST CANCER RESEARCH, 2005, 7 (05)
  • [23] Metabolism of antipsychotics and CYP2D6 genotype
    Schmider, J
    Walter, S
    Sachse, C
    Bauer, S
    Müller-Oerlinghausen, B
    Roots, I
    Brockmöller, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R459 - R459
  • [24] CYP2D6 genotype and tardive dyskinesia
    Sajjad, SHA
    BRITISH JOURNAL OF PSYCHIATRY, 1997, 170 : 580 - 580
  • [25] CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6
    MCLEOD, HL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 463 - 463
  • [26] CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting
    McElroy S.
    Richmond J.
    Lira M.
    Friedman D.
    Silber B.M.
    Milos P.M.
    Sachse C.
    Brockmöller J.
    Roots I.
    AAPS PharmSci, 2 (4): : 1 - 11
  • [27] CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting
    McElroy, S
    Richmond, J
    Lira, M
    Friedman, D
    Silber, BM
    Milos, PM
    Sachse, C
    Brockmöller, J
    Roots, I
    AAPS PHARMSCI, 2000, 2 (04): : art. no. - 33
  • [28] CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene
    Skierka, Jennifer M.
    Walker, Denise L.
    Peterson, Sandra E.
    O'Kane, Dennis J.
    Black, John Logan, III
    PHARMACOGENOMICS, 2012, 13 (08) : 951 - 954
  • [29] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [30] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
12345